Cyclophosphamid

Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)

Rescue of Nephrons With ALE.F02 (RENAL-F02)

CD30 CAR for CD30+ NSGCT

A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

ATG Plus Low-dose PT-Cy for GVHD Prevention

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer

TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer

Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia

Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies

Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis

Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia

Natural Killer(NK) Cell Therapy in r/r AML